Skip to main content

Table 4 Bayesian Analysis of Change from Baseline CAT Score up to Month 6

From: CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial

 PlaceboDNX 5 mgDNX 10 mgDNX 25 mgDNX 35 mgDNX 50 mg
N10110210010310099
Baseline CAT Total Score18.2 (7.72)18.3 (7.11)17.8 (6.99)18.2 (7.80)19.1 (6.74)17.5 (6.20)
n849486878583
Mean Change from Baseline (90% CI)−1.39 (−2.29,-0.47)−1.39 (− 2.27,-0.51)−1.23 (− 2.13,-0.32)−0.97 (−1.91,-0.04)−1.56 (− 2.47,-0.64)− 1.32 (− 2.24,-0.39)
Mean Difference from Placebo (90% CI) −0.01 (− 1.29,1.29)0.16 (− 1.12,1.46)0.41 (− 0.88,1.69)−0.17 (− 1.48,1.10)0.07 (− 1.26,1.37)
  1. N Number enrolled, n Number of subjects with analysable data at the current time point; CI Credible interval